微创玻璃体手术时代:糖尿病视网膜病变手术的新认识  

The era of minimally invasive vitreous surgery:new insights into diabetic retinopathy surgery

作　　者：吕林[1] 陈士达 Lyu Lin;Chen Shida(State Key Laboratory of Ophthalmology,Zhongshan Ophthalmic Center,Sun Yat-sen University,Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science,Guangdong Provincial Clinical Research Center for Ocular Diseases,Guangzhou 510060,China)

机构地区：[1]中山大学中山眼科中心,眼科学国家重点实验室,广东省眼科视觉科学重点实验室,广东省眼部疾病临床医学研究中心,广州510060

出　　处：《中华眼底病杂志》2022年第1期1-5,共5页Chinese Journal of Ocular Fundus Diseases

摘　　要：玻璃体切割手术(PPV)是糖尿病视网膜病变(DR)尤其是增生期DR的首选手术方式。针对DR的PPV比较全面的涉及到了PPV各个方面的操作,是视网膜外科医生成熟的标志之一。随着微创PPV及围手术期抗新生血管药物的广泛应用,其手术指征及手术时机、围手术期用药、手术中玻璃体的处理、是否联合白内障手术均发生了较大变化,需要有新的认识。临床应努力开展新条件下DR手术时机、围手术期药物应用等循证医学研究,为DR的手术治疗提供新的理论依据。Vitrectomy is the preferred surgical method for diabetic retinopathy,especially in the stage of proliferative diabetic retinopathy.Vitrectomy for diabetic retinopathy involves all aspects of vitrectomy,which is one of the signs of maturity of retinal surgeons.With the application of minimally invasive vitrectomy and perioperative anti-neovascularization drugs,indications and timing of surgery,perioperative medication,management of vitreous,and whether combined with cataract surgery have changed greatly,and new understanding is needed.Evidence-based clinical research on the timing of diabetic retinopathy surgery and perioperative drug use should be carried out to provide a new theoretical basis for the surgical treatment of diabetic retinopathy.

关 键 词：糖尿病视网膜病变 玻璃体切除术 外科手术 微创性 述评 

分 类 号：R587.2[医药卫生—内分泌] R779.6[医药卫生—内科学]